In this study, we investigated how the hormonal regulation of spermatogenesis modulates 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB) isozyme expression in two mouse spermatogenic cell lines, GC-1 spg and GC-2 spd (ts). For this purpose, TM4 Sertoli cells were used to obtain conditioned medium that was treated or not with dihydrotestosterone for 2 days [dihydrotestosterone conditioned medium (TCM) and basal conditioned medium (BCM), respectively]. We observed an increase in the expression of PFKFB4 along with a decrease in PFKFB3 in spermatogenic cell lines treated with TCM. These effects were inhibited by the antiandrogen drug flutamide and by heat-inactivated TCM, indicating the protein nature of the TCM mediator and its dependence on Sertoli cell stimulation by dihydrotestosterone. In addition, adult rat testes treated with the GnRH antagonist Degarelix exhibited a reduction in the expression of PFKFB4 in germ cells. Addition of exogenous FGF-2 mimicked the changes in the Pfkfb gene expression, whereas neutralizing antibodies against FGF-2 abolished them. Interestingly, similar effects on Pfkfb gene expression were observed using different MAPK inhibitors (U-0126, PD-98059, and H-89). Luciferase analysis of Pfkfb4 promoter constructs demonstrated that a putative CRE-binding sequence located at Ϫ1,463 relative to the transcription start site is required to control Pfkfb4 gene expression after TCM treatment. Pulldown assays showed the binding of the CREB transcription factor to this site. Altogether, these results show how the paracrine regulation orchestrated by Sertoli cells in response to testosterone controls glycolysis in germ cells.
fibroblast growth factor; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase; mitogen-activated protein kinase kinase; extracellular signal-regulated kinase; cAMP response element-binding protein; fructose-2,6-bisphosphate; glycolysis; spermatogenesis; sperm production FRUCTOSE-2,6-BISPHOSPHATE (Fru-2,6-P 2 ) is the most powerful allosteric activator of 6-phosphofructo-1-kinase and inhibitor of fructose-1,6-bisphosphatase. Because of its antagonistic actions on these enzymes, Fru-2,6-P 2 plays a crucial role in governing flux along glycolytic and gluconeogenic pathways (42, 59) . This metabolite has been reported in spermatozoa at a concentration similar to that found in other tissues (19, 44) . The synthesis and degradation of Fru-2,6-P 2 is catalyzed by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB). Distinct isoforms of this enzyme have been identified in mammalian tissues (47, 59) , all functioning as homodimers with an amino-terminal kinase and a carboxy-terminal bisphosphatase domain. Although the catalytic core structure is highly conserved among the isozymes, the amino and carboxy termini are the areas of less homology. The isozymes are encoded by four independent genes, Pfkfb1-4 (42, 46) . A specific combination of isozymes can be simultaneously present in a particular tissue, depending on its metabolic requirements (16) . Previously, we cloned a testisexpressed Pfkfb gene that corresponds to the Pfkfb4 gene (32) , which encodes the testis PFKFB4 isozyme (50, 57) .
The process of spermatogenesis is regulated by a complex interaction of endocrine and paracrine signals provided by the local environment (24, 35, 53) . At puberty, the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus leads to the release of gonadotropins. Later, these hormones, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), act on the testis to regulate spermatogenesis. LH binds to receptors on the surface of Leydig cells in the testis to stimulate the production of testosterone, which diffuses into the seminiferous tubules. Within the tubules, only Sertoli cells possess receptors for testosterone and FSH; therefore, these cells are the major targets of the ultimate hormonal signals that regulate spermatogenesis (34, 51) . Based on this mechanism of action, experimental models using GnRH antagonists are a good method for testing the effects of the lack of testosterone (7) . However, the mechanisms by which androgens affect spermatogenesis remain poorly understood. Sertoli cells provide substrates that are required to fuel germ cell metabolism (lactate or pyruvate), growth regulatory factors (stem cell factor), transforming growth factor (TGF)-␣ and TGF␤, fibroblast growth factor (FGF), or epidermal growth factor (EGF) and hormones that regulate the development of the male reproductive structures or feedback to regulate the hormonal signals affecting Sertoli cells (mullerian-inhibiting substance and inhibin) (35, 53) .
FGFs are a large family of multifunctional peptide growth factors that are identified in a variety of organisms and have roles in many cellular processes, including mitogenesis, differentiation, migration, and cell survival (11) . In testis, FGF-2 is located in Sertoli, Leydig, and germ cells, specifically in type A spermatogonia, primary pachytene spermatocytes, and elon-gating spermatids (27) . FGF-2 (basic FGF) is a survival factor for Sertoli cells and a mitogenic factor for gonocytes (58) . Some studies have also suggested that FGF is involved in the proliferation and differentiation of testicular cells and may also be involved in the regulation of spermatogenesis (26, 36) . FGF binds to and activates a family of receptor tyrosine kinases. This leads to the activation of multiple signal transduction pathways, for instance, the MAPKs ERK1 and ERK2, which are present and active in sperm cells (2, 3, 28, 30, 31) . The two forms of MAPK, ERK1 and ERK2, are expressed in similar quantities in all spermatogenic cells at different stages (2) . However, evidence of ERK1/2 phosphorylation has been detected only in early spermatogenic cells from primitive spermatogonia to zygotene spermatocytes (30) . Indeed, ERK translocates to the nucleus and activates several transcription factors, like c-Fos, c-Jun, Elk-1, Ets, STAT, and CREB, culminating in proliferation and differentiation. Thus, ERK1/2 may be involved in posttranscriptional regulation of a subset of genes or regulation of translation of specific RNA targets during meiosis (2, 3) .
PFKFB4 and PFKFB3 isozymes are present in the adult testes (18, 19) . PFKFB3 is located across the seminiferous epithelium, whereas expression of PFKFB4 is restricted to the spermatogenic cells, being the only one present in mature spermatozoa (19) . This differential distribution supports the idea that the cell-specific isozymes are able to adapt their kinetic and regulatory enzymatic properties to the metabolic demand of a particular tissue or cell status. Thus, in parallel with spermatogenesis and spermiogenesis, PFKFB isozyme expression switches from PFKFB3, which is required during the proliferative phase, to the testis isoform PFKFB4, which is germ cell specific (19) . Here, we examine the cross-talk between testosterone and the expression of PFKFB isozymes. For this purpose, we used TM4 Sertoli cells treated or not with dihydrotestosterone (DHT) to obtain conditioned media, i.e, DHT conditioned medium (TCM) and basal conditioned medium (BCM), respectively. As an in vivo model of germ cell differentiation, we have used two mouse-derived cell lines, GC-1 spg [type B spermatogonia (22) ] and GC-2 spd (ts) [spermatocyte arrested at a premeiotic stage (21, 67) ], which have been used extensively in the literature to study specific gene expression of germ cells (10, 43, 52, 65) . To corroborate the results in an in vivo model, we have used rat testes tissues treated with the GnRH antagonist Degarelix (7). The results obtained show that, in response to DHT stimulation, Sertoli cells produce and secrete FGF-2, which is involved in the modulation of PFKFB isozymes in germ cells by activation of the MEK/ERK/CREB pathway.
MATERIALS AND METHODS
Reagents. DHT (5␣-androstan-17␤-ol-3-one) and flutamide were obtained from Sigma-Aldrich (St. Louis, MO). EGF and FGF-2 were purchased from Peprotech (London, United Kingdom). Degarelix (FE 200486 
was from Ferring Pharmaceuticals A/S (Copenhagen, Denmark). The vehicle of Degarelix was 5% mannitol diluted in sterile distilled water. The Degarelix solutions were prepared just before administration to animals. The MAPK inhibitors U-0126, PD-98059, and H-89 were purchased from Sigma-Aldrich. The FGF receptor (FGFR)1 inhibitor SU-5402 was obtained from Calbiochem (La Jolla, CA).
Animals. Sprague-Dawley male rats weighting 200 -300 g were injected subcutaneously in the scapular region with a single dose of vehicle or GnRH antagonist (Degarelix; 200 g/kg) to chemocastrate them. Afterward, rats were allowed to recover in individual cages with food and water available ad libitum. Blood sampling (300 -400 l) was performed through the sublingual vein, and blood was collected in standard K 3-EDTA tubes. Plasma was extracted by centrifugation at 3,000 rpm for 10 min and then stored at Ϫ20°C until determination of Degarelix using LC-MS/MS. After 3 mo, treated and control rats were euthanized and testes collected, rinsed with PBS, fixed in 4% paraformaldehyde for 16 h, and then maintained in 30% PBS-sacharose for 48 h.
Cell culture and transfections. TM4 mouse Sertoli cells were from ATCC (CRL-1715). They were originated from immature testes of normal 11-to 13-day-old BALB/c mice and characterized originally as Sertoli cells based on their morphology, hormone responsiveness, and metabolism of steroids (33) . TM4 cells were grown in a 1:1 mixture of Ham's F-12 medium and Dulbecco's modified Eagle's medium (DMEM) supplemented with 1-2 g/l sodium bicarbonate and 15 mM HEPES, 5% horse serum, and 2.5% fetal calf serum (FCS) and incubated in a humidified atmosphere of 10% CO 2 and 90% air at 37°C. Since its generation, this cell line has been used in numerous studies with results similar to those obtained using primary cultures of Sertoli cells (45, 49, 71) .
The GC-1 spg mouse spermatogonia cell line was from ATCC (CRL-2053). It was originated from inmortalized type B spermatogonia and shows characteristics of a stage between type B spermatogonia and primary spermatocytes (22) . These cells express testis-specific isoproteins and can differenciate from spermatogonia into spermatids (65) . GC-1 spg cells were grown in DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10% FCS, and 1 mM Na-pyruvate and incubated in a humidified atmosphere of 10% CO2 and 90% air at 37°C.
The GC-2 spt (ts) mouse spermatocyte cell line was from ATCC (CRL-2196). It was originated from freshly isolated spermatocytes (21) , which have lost their differentiation potential and have been arrested at a premeiotic stage (67) . This cell line was grown in DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 10% FCS and incubated in a humidified atmosphere of 10% CO2 and 90% air at 37°C. Both germ cell lines have been used extensively to study gene expression in germ cells through arrays, promoter studies of germ cell-specific genes, apoptosis, etc. (10, 43, 52, 65) .
The various promoter-reporter fusion plasmids (1 g) and 60 ng of the pSV40-␤-galactosidase control vector (Promega, Madison, WI) were cotransfected into cells using Lipofectamine 2000 reagent (Life Technologies, Eggernstein, Germany) according to the manufacturer's instructions. Luciferase activities were assayed as described previously (18) . Luciferase values are expressed as luciferase activity corrected for ␤-galactosidase activity. Transfections were performed at least in triplicate, and the results are expressed as fold stimulation compared with normalized luciferase activity measured in basal condition, which was set to 1.0.
Plasmid constructions. Pfkfb4 and Pfkfb3 human promoter constructs were described by Gómez et al. (18) and Navarro-Sabaté et al. (41) , respectively. Pfkfb4/Ϫ2,100 construct was generated by cutting the Pfkfb4/Ϫ3,587 construct with SfiI and re-ligating the resulting vector. A pGL2-basic vector with the c-fos minimal promoter unit served as the basis for reporter constructs CREwt-c-fos and CREmut-cfos. A fragment of 30 nucleotides of the Pfkfb4 promoter (from Ϫ1,476 to Ϫ1,446) containing the putative CRE motif (marked in bold type: 5=-GAGGAGGCGGGAAACTGCAGGAGTCCGGTG-3=) was subcloned to obtain the CREwt-c-fos construct. The same 30-nucleotide fragment with a mutation in two base pairs in the CRE-binding site (lower-case: 5=-GAGGAGGCGGGAAACacCAGGAGTCCGGTG-3=) was used to generate the CREmut-c-fos construct. All of them were confirmed by sequencing.
Conditioned medium production. To prepare the conditioned medium (CM), TM4 cells were seeded in 100-mm cell culture dishes and grown in DMEM-F-12 containing 5% horse serum and 2.5% FCS until 80% confluence. Then, the medium was replaced with DMEM-F-12 without serum. After 24 h, the serum-free medium was refreshed with vehicle (0.1% ethanol and/or 0.1% DMSO), 10 nM DHT (in 100% ethanol), or 10 nM DHT plus 1 M flutamide (in DMSO). After 2 days, these media were collected, centrifuged at 1,000 rpm for 5 min to eliminate cell debris, and stored at Ϫ20°C until use. We refer to these conditioned media as basal conditioned medium (BCM), testosterone conditioned medium (TCM), and TCM plus flutamide, respectively. TCM was heat-denaturized by boiling for 15 min, followed by 45 min cooling on ice.
Western blot analysis and semiquantification. Cells were rinsed in cold PBS and scraped into lysis buffer (1ϫ PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease and phosphatase inhibitors (0.1 g/ml Benzamidin, 10 g/ml aprotinin, 10 g/ml pestatin A, 10 g/ml leupeptin, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1 mM phenylmethylsulfonyl fluoride) at 4°C. Lysates were incubated on ice for 30 min and homogenized by vortexing. The suspension was centrifuged at 14,000 rpm for 10 min, and the supernatant was mixed with loading buffer, followed by incubation at 95°C for 5 min. Samples were subjected to SDS-PAGE, as described Cubillos-Rojas et al. (12) , followed by transfer to nitrocellulose membranes (Pharmacia, Uppsala, Sweden). Blots were blocked with 5% fat-free milk in 10 mM Tris-buffered saline (pH 8.0) for 1 h and incubated overnight at 4°C with PFKFB4 (18), PFKFB3 (48), ␣-tubulin monoclonal antibody (1:4.000 dilution; Sigma), p-ERK 42/44 (1:1,000 dilution; Cell Signaling Technology, Beverly, MA), p-CREB (1:500 dilution; Cell Signaling Technology), p-MSK-1 (mitogen-and stress-activated protein kinase-1; 1:1,000 dilution; Cell Signaling Technology), total ERK (1:1,000 dilution; Upstate Biotechnology), and total CREB (1:1,000 dilution; Cell Signaling Technology).
The membrane was washed in Tris-buffered saline solution containing 0.05% Tween-20 and incubated for 1 h at room temperature with the corresponding secondary antibodies horseradish peroxidaseconjugated anti-rabbit IgG and horseradish peroxidase-conjugated anti-mouse IgG (1:10,000 dilution; GE healthcare). Peroxidase activity was detected with ECL reagent (Pierce, Rockford, IL) and visualized with luminescent image analyzer LAS 3000 (Fujifilm). Bands were digitized and optical densities analyzed using Multi Gauge (Version 3.0; Amersham Biosciences, Piscataway, NJ). Protein levels were quantified by computer analysis since the ratio between each immunoreactive band and the levels of ␣-tubulin were expressed as a percentage of untreated cultures.
Indirect inmunofluorescence analysis. Fixed testes were immersed in OCT compound (Tissue-Tek; Miles, Elkhart, IN) and frozen immediately. Sections (3 m) were cut, rinsed with PBS, and blocked in PBS-0.02%, Triton X-100, and 1% normal goat serum in a humidified chamber. Coverslips were incubated with specific rabbit antibodies against PFKFB4 (ABGENT cat. no. AP8154c, 1:100 dilution) and PFKFB3 [1:50 dilution (48)] in blocking solution overnight at 4°C in a humidified chamber. Sections were rinsed with PBS-0.1% Triton X-100 and incubated for 1 h at room temperature with the secondary goat anti-rabbit Alexa Fluor 488 (Invitrogen, Molecular Probes, Eugene, OR). 4,6-diaminido-2-phenylindole (DAPI; 1:1,000) contrastaining was used as a cell nucleous marker (Invitrogen) at 4°C in a dark chamber. Afterward, sections were rinsed with PBS-0.01% Triton, mounted on coverslips using Mowiol (Calbiochem, San Diego, CA), and viewed under a confocal TSC-SL Leica microscope. Staining was evaluated in three samples of each group.
Metabolite determination. Fru-2,6-P 2 was determined by following the method described by Van Schaftingen et al. (60) . Protein concentration was determined by the Bradford-based Bio-Rad assay.
Neutralizing antibody assay. Neutralizing antibody anti-FGF-2-basic FGF clone bFM-1 was purchased from Millipore. For neutralizing FGF activation, CM was preincubated with 4 g/ml mouse monoclonal anti-FGF-2 or anti-mouse IgG antibodies for 2 h at 37°C with agitation. Cells were then treated for 4 h with CM pretreated with neutralizing antibodies.
Biotinylated oligonucleotide precipitation assays. GC-1 spg cells were treated with BCM, TCM, or BCM plus FGF-2 for 40 min and then rinsed with PBS twice and scraped into lysis buffer (100 mM KCl, 10 mM HEPES, pH 7.9, 10% glycerol, 1 mM DTT, 5 mM MgCl 2, and 0.1% Nonidet P-40) supplemented with protease inhibitors, as described above. Biotinylated oligonucleotides encoding the Ϫ1,436 to Ϫ1,430 fragment of the Pfkfb4 promoter were incubated for 2 h with cell extracts in the presence of 1 g of poly(dI-dC) (GE Healthcare) and collected with streptavidin-agarose beads (GE Healthcare). Bound CREB was detected by immunoblotting.
Isolation and analysis of RNA. GC-1 spg and GC-2spd (ts) cells were homogenized, and total RNA was obtained using the RNA isolation reagent Ultraspec (Biotecx Laboratories, Houston, TX), following the manufacturer's protocol. The concentration and purity of all RNA were determined using the A 260nm/A280nm ratio and formaldehyde gel electrophoresis. Single-stranded cDNAs were obtained from reverse transcription (RT) of total RNA using the high-capacity cDNA archive kit (Applied Biosystems, Norwalk, CA), following the manufacturer's instructions. An aliquot of the resulting single-stranded cDNA (2 g) was used in the real-time PCR described below.
Real-time quantitative PCR. RT products (2 g) were subsequently used as template for PCR. Pfkfb3 and Pfkfb4 were specifically amplified using the probe/primer sets for mouse Mm 00504650_m1 and Mm 01235506_m1, respectively (Taqman Gene Expression Assays; Applied Biosystems). The threshold cycle number was calculated, and the relative amount of the specific mRNA in each sample was calculated using the standard curve generated with the same probe/ primer set on adult testis total RNA. The relative expression of each gene was normalized to that of actin.
Statistics. Unless stated otherwise, each experiment was repeated three to eight times using triplicate cultures, and the results are presented as means Ϯ SE and evaluated using the GraphPad InStat 5 program (GraphPad Software, San Diego, CA). Statistically significant differences between the experimental groups were determined by analysis of variance followed by Bonferroni posttests. Data were considered statistically significant when P Ͻ 0.05, P Ͻ 0.01, and P Ͻ 0.001.
RESULTS

TCM regulates Pfkfb gene expression.
To test whether the change in the expression of Pfkfb isozymes described during the last stages of spermatogenesis (19) is due to a paracrine regulation, the mouse Sertoli cell line TM4 was cultivated with either vehicle or 10 nM 5␣-androstan-17␤-ol-3-one (DHT) to obtain BCM and TCM, respectively. After 48 h, these media were added to the spermatogenic cell lines GC-1 spg and GC-2 spd (ts). TCM treatment increased PFKFB4 protein expression, being statistically significant in GC-2 spd (ts) cells, although treatment with TCM significantly reduced the expression of PFKFB3 protein by half in both cell lines (Fig. 1A) . Then, we measured the levels of Fru-2,6-P 2 (Fig. 1B) , whose concentration increased significantly after the cells were treated with TCM. Direct hormonal treatment with 10 nM DHT (70) did not show any effect on the PFKFB expression by either Western blot assay in germ cells (data not shown) or luciferase assays in TM4 cells (18) . Using real-time quantitative PCR (qPCR), we analyzed samples after 24 h of TCM treatment, obtaining enhanced Pfkfb4 gene transcription over basal expression in both spermatogenic cells [P Ͻ 0.005 in GC-1 spg and P Ͻ 0.01 in GC-2 spd (ts)]. In contrast, Pfkfb3 gene expression decreased significantly (P Ͻ 0.01) over basal expression in both the GC-1 and GC-2 cell lines. To assess the temporal pattern of Pfkfb transcriptional regulation after TCM treatment, we performed a detailed time course experiment from 0 to 24 h. On the one hand, Pfkfb4 gene expression increased progressively over time, peaking between 6 and 8 h of treatment and being statistically significant in the GC-2 spd (ts) cells (P Ͻ 0.001; Fig. 1C, left) . On the other hand, Pfkfb3 gene expression was halved over the same period of time in both cell lines (P Ͻ 0.01; Fig. 1C, right) .
Luciferase assays of GC-1 spg and GC-2 spd (ts) cells transiently transfected with Pfkfb4/Ϫ2,100 and Pfkfb3/Ϫ3,566 promoter constructs showed a significant increase (P Ͻ 0.001) in luciferase activity of the Pfkfb4 promoter construct and a significant decrease (P Ͻ 0.001) in luciferase activity of the Pfkfb3 promoter construct after TCM treatment, in agreement with RT-qPCR results (Fig. 1D) . To discern the minimal promoter region of the human Pfkfb4 promoter required for TCM responses, GC-1 spg and GC-2 spd (ts) cells were transiently transfected with progressively deleted Pfkfb4 promoter constructs.
In both cell lines, TCM increased luciferase activity in the constructs Pfkfb4/Ϫ2,100 and Pfkfb4/Ϫ1,800, but no effect was shown for Pfkfb4/Ϫ1,077, Pfkfb4/Ϫ428, or Pfkfb4/Ϫ166 (Fig.  1D) . Hence, the sequence of 800 nucleotides included from Ϫ1,800 to Ϫ1,077 of the Pfkfb4 gene promoter is involved in the transcriptional response to the TCM treatment.
A testosterone-dependent protein mediates TCM action on PFKFB4 and PFKFB3 expression. To confirm that the effect of TCM on Pfkfb4 and Pfkfb3 mRNA expression in spermatogenic cells was due to DHT action, TM4 cells were treated with DHT plus flutamide (1 M), which competes with DHT for binding to androgen receptors. Furthermore, we also denatured TCM by heat inactivation to check whether any soluble factors present in TCM and responsible for controlling Pfkfb4 and Pfkfb3 expression were heat sensitive and, therefore, proteins. Thus, the GC-1 spg cell line was transiently transfected with Pfkfb4/Ϫ2,100 or Pfkfb3/Ϫ3,566 promoter constructs, and then cells were treated with BCM, TCM, or their inactivated forms with flutamide or heat inactivated. Results showed that both nonfunctional media significantly decrease the action of TCM over Pfkfb4/Ϫ2,100 or Pfkfb3/Ϫ3,566 promoter constructs, but no response was detected when BCM plus flutamide or heat-inactivated BCM was used ( Fig. 2A) . Similar results were obtained when mRNA expression by RT-qPCR was analyzed after 24 h of treatment under the same conditions (Fig. 2, B and RT-qPCR analysis of Pfkfb4 and Pfkfb3 expression was performed on RNA extracts from GC-1 spg and/or GC-2 spd (ts) cells after they were treated for 24 h with BCM, TCM, TCM plus flutamide, or heat-inactivated TCM (results are expressed as fold of induction compared with corresponding BCM condition; n ϭ 3 for each condition). **P Ͻ 0.01; ***P Ͻ 0.001. C). Thus, neither Pfkfb4 nor Pfkfb3 mRNA levels were modified in GC-1 spg or GC-2 spd (ts) cells when they were treated with the nonfunctional TCM. Taken together, these results suggest that, after being stimulated with DTH, TM4 cells secrete protein soluble factors that are responsible for controlling Pfkfb4 and Pfkfb3 gene expression in both GC-1 spg and GC-2 spd (ts) cells.
To corroborate these data with PFKFB3 and PFKFB4 protein expression in vivo, we performed immunofluorescence experiments using testes tissue from chemically castrated rats by administration of the GnRH antagonist (Degarelix) (7) . Treated animals with Degarelix showed testes significantly smaller than those of control rats (500 Ϯ 20 and 3,600 Ϯ 110 mg, respectively). The assessment of Degarelix exposure confirmed a level frequently observed for a complete GnRH receptor blockade, and the size of the testicles documents a complete blockade of the pituitary-gonadal axis. As expected, Fig. 3 . Immunofluorescence of PFKFB4 and PFKFB3 on rat testes treated with Degarelix. A representative immunofluorescence microscopy image of control and Degarelix-treated animals is shown. Top: PFKFB4 expression was measured using rabbit anti-PFKFB4 (ABGENT cat. no.: AP8154c). Bottom: PFKFB3 expression was measured using a rabbit anti-PFKFB3 (48) . Secondary goat anti-rabbit Alexa 488 antibody was incubated for 1 h at room temperature. 4,6-Diaminido-2-phenylindole contrastaining was used as cell nucleous marker. Staining was evaluated in 3 samples of each group showing similar results. immunofluorescence results showed that PFKFB4 protein expression decreased significantly in testes of treated rats compared with control tissue, whereas PFKFB3 protein expression remained elevated (Fig. 3) .
FGF-2 present in TCM regulates the Pfkfb4 and Pfkfb3 gene expression.
Investigators have found that androgen stimulation of Sertoli cells leads to increased levels of secreted growth factors and their receptors, such as EGF or FGF-2 (20, 54) . On the basis of these reported findings, we investigated whether these growth factors could be one of the soluble factors present in TM4 CM. We next examined whether the treatment of germ cells with FGF-2 (20 ng/ml) or EGF (10 g/ml) could mimic the TCM action on Pfkfb4 and Pfkfb3 expression. GC-1 spg and GC-2 spd (ts) cells were transiently transfected with Pfkfb4/Ϫ1,800 and Pfkfb3/Ϫ3,566 constructs and treated with BCM, TCM, and BCM plus EGF or FGF-2. Both EGF and FGF-2 increased Pfkfb4 gene transcription, whereas only FGF-2 affected Pfkfb3 transcription. Thus, FGF-2 emulates the effect of TCM on Pfkfb4 and Pfkfb3 mRNA expression (Fig. 4A) .
To better understand the transcriptional response of Pfkfb4 to the TCM treatment, we examined whether EGF and FGF-2 share the same transcriptional response region in the Pfkfb4 promoter as TCM. Figure 4B shows transient transfection of the GC-1 spg cell line treated with BCM, TCM, and BCM plus EGF or FGF-2. EGF increased luciferase activity in all constructs, i.e., Pfkfb4/Ϫ1,800, Pfkfb4/Ϫ1,077, Pfkfb4/Ϫ428, and Pfkfb4/Ϫ166. In contrast, FGF-2 increased luciferase activity only with Pfkfb4/Ϫ1,800. Thus, only FGF-2 mimics the action of TCM over the Pfkfb4 gene promoter and may be the mediator of the TCM response.
Next, we assessed whether FGF-2 can induce the same response as TCM via FGF receptors. To this end, we used the FGFR tyrosine kinase activity inhibitor SU-5402. This is an ATP mimetic that inhibits FGFR1 tyrosine phosphorylation by binding to the ATP-binding site (11) . Therefore, we evaluated the effect of SU-5402 by RT-qPCR and transient transfection assays in GC-1 spg and GC-2 spd (ts) cells. SU-5402 reversed the increase in Pfkfb4 mRNA induced by TCM in GC-1 spg and GC-2 spd (ts) (50 and 75% of reduction, respectively). In contrast, in the same conditions, SU-5402 induced a two-to threefold increase in Pfkfb3 mRNA expression (Fig. 4C) . Similar results were obtained when we analyzed the luciferase activity on both promoter constructs (Fig. 4D) . Treatment with TCM plus 20 M SU-5402 significantly reversed TCM effects on Pfkfb4 and Pfkfb3 transcription. Nevertheless, because Pfkfb3 mRNA levels in the TCM plus SU-5402 condition are slightly higher than those in the basal (BCM) condition, we cannot exclude the possibility that other paracrine factors could be present in TCM and partially contribute to its transcriptional regulation.
To corroborate the role of FGF-2 as the TCM mediator, we used a neutralizing antibody against FGF-2. Treatment with the blocking monoclonal anti-FGF-2 antibody reduced Pfkfb4 mRNA induction by TCM by ϳ50% (Fig. 4E) . In contrast, there was no significant attenuation when we used an antimouse IgG antibody. Additionally, when GC-1 spg and GC-2 spd (ts) cells were exposed to exogenous FGF-2, Pfkfb4 mRNA increased in both cell lines, whereas it was partially (45%) antagonized by the neutralizing FGF-2 antibody. Consistent with these results, the inhibition of Pfkfb3 mRNA expression by TCM was reversed when the neutralizing FGF-2 antibody was added to the medium (Fig. 4F) . Taken together, all of these results show that FGF-2, which is present in TCM, is responsible for promoting Pfkfb4 and inhibiting Pfkfb3 gene transcription via the FGFR.
Pfkfb4 and Pfkfb3 genes are controlled through TCM/MEK/ ERK pathway activation. One of the main signaling pathways regulated by FGF-2 and FGFR is the Ras/MEK/ERK pathway. We next examined the involvement of the ERK kinase pathway in TCM action. Thus, we treated GC-1 spg and GC-2 spd (ts) cells with BCM, TCM, or BCM plus FGF-2 at different times and analyzed the activation of the MEK/ERK pathway. Rapid induction of ERK phosphorylation was observed when cells were treated by TCM or BCM plus FGF-2, which correlated with an induction of phosphorylation of MSK-1, a downstream mediator of ERK signaling (Fig. 5A) . Moreover, we pretreated spermatogenic cells with SU-5402 to inhibit FGFR kinase activity and autophosphorylation. TCM-induced phosphorylation of ERK was completely abolished by 20 M SU-5402 (Fig. 5B) . As a control, we treated cells with FGF-2 and evaluated FGF-2-mediated ERK phosphorylation in the presence or absence of SU-5402, obtaining similar results (Fig. 5B) . p-MSK-1 phosphorylation was completely blocked when spermatogenic cells were cultivated with the FGFR inhibitor SU-5402 (Fig. 5B) .
To confirm the participation of ERK signaling in the TCM control of Pfkfb genes, spermatogenic cells were preincubated with several specific inhibitors. SU-5402 was used to block FGF-2 signaling, U-0126 and PD-098059 were used as MEK inhibitors, and H-89 was used to inhibit MSK-1 signaling. Pfkfb4 and Pfkfb3 transcriptional activity was analyzed by RT-qPCR, in GC-1 spg and GC-2 psd (ts), and by luciferase assays in GC-1 spg (Fig. 5, C-F) . SU-5402, U-0126, PD-098059, and H-89 completely abolished TCM-dependent Pfkfb4 transcriptional upregulation (Fig. 5, C and D) . Simultaneusly, Pfkfb3 gene expression was reversed by addition of the same MAPK inhibitors to the culture media, although in this case, other indirect effects cannot be ruled out (Fig. 5, E  and F) .
Participation of CREB in Pfkfb4 gene induction. CREB is phosphorylated and activated by the MEK/ERK pathway (61) . In this context, we examined the role of CREB activation in TCM action in spermatogenic cells. Thus, we analyzed CREB phosphorylation in GC-1 spg and GC-2 spd (ts) cells by Western blot in the presence of BCM, TCM, or BCM plus FGF-2. CREB phosphorylation at Ser 133 increased after TCM treatment compared with the BCM condition in GC-1 spg (Fig. 6A ) and GC-2 spd (ts) cells (data not shown). Moreover, the addition of FGF-2 to BCM kept the level of p-CREB similar to that of TCM-treated cells.
According to Fig. 1D , the region from Ϫ1,800 to Ϫ1,077 seems to contain the CRE response element. An extensive analysis of that region by the computer database TRANSFAC, version 7.0, revealed a putative CRE consensus site near the position Ϫ1,463 relative to the transcription start site in the 5= flanking region of the human Pfkfb4 gene. To test the TCM responsiveness of this region, we subcloned a 30-nt fragment around this promoter region into a c-fos minimal promoter unit in a luciferase reporter vector. This fragment, encompassing Ϫ1,476/Ϫ1,446 relative to the transcription start site, was used to create two reporter constructs, CREwt-cfos and CREmutcfos. Both constructs were identical except that the latter contained a mutation in two base pairs in the putative CREbinding site. To study the enhancer activity, we measured relative luciferase activity of GC-1 spg cells transfected with CREwt-cfos or CREmut-cfos constructs and 60 ng of ␤-galactosidase expression vector to normalize transfection efficiencies in the presence of BCM or TCM. Although wild-type and mutated constructs displayed similar basal reporter activities, a 1.7-fold increase was detected in the CREwt-c-fos construct following TCM treatment, whereas the CREmut-c-fos was not modified (Fig. 6B) . To corroborate the importance of the CRE-binding site located at the Ϫ1,463 position as the mediator of the TCM responsiveness in the Pfkfb4 promoter, we performed biotinylated oligonucleotide pulldown assay followed by Western blot analysis using GC-1 spg cell extracts obtained after 40 min with BCM, TCM, or BCM plus FGF-2 treatments. Western blot revealed the presence of CREB complexes in the streptavidin-sepharose beads incubated with BCM, TCM, and FGF-2 extracts (Fig. 6C) . Taken together, these results show that CREB binds to the CRE consensus sequence from Ϫ1,463 of the Pfkfb4 gene promoter.
DISCUSSION
Previously, we established that in rat testis the maximum expression of PFKFB3 gene was detected before puberty, whereas that of PFKFB4 was observed in adulthood (19) . We also showed that PFKFB3 isozyme was present in the cytoplasm of Sertoli cells and spermatogonia. In contrast, expression of PFKFB4, which was located only in germ cells, increased with age and showed maximum expression at elongating spermatids (19) . These data confirmed previous results linking PFKFB3 expression to undifferentiated and proliferating cells (1, 48, 15, 16, 48, 68, 69) . Once a cell differentiates, the expression of this isozyme is switched off and replaced by one tissue-specific PFKFB isozyme. In testis, PFKFB4 replaces PFKFB3, which is the source of the Fru-2,6-P 2 in rat sperm (19) . The change in the expression of PFKFB proteins may be of great importance in maintaining the metabolism of germ cells since spermatogenic cells undergo a differentiation change to their carbohydrate metabolism. These metabolic changes determine that meiotic spermatogenic cells (e.g., pachytene spermatocytes) have a higher glycolytic flux than postmeiotic cells (spermatids) (5) . Moreover, the metabolic changes are accompanied by a shift in glycolytic enzymes, which have a testis-specific isoform (6, 29, 40, 66) .
The results presented herein demonstrate that DHT induces the paracrine secretion of FGF-2 by Sertoli TM4 cells, which is responsible for modulating PFKFB isozyme expression in germ cells. The antagonistic actions of the antiandrogen drug flutamide, which competes with DHT for binding to its receptor, the lack of effect using heat-inactivated TCM, immunofluorescence results in chemocastrated animals, the low specificity of the EGF actions, the lack of response using an FGF receptor inhibitor (SU-5402), or a neutralizing antibody against FGF-2, all indicate that this growth factor is responsible for the isozyme transition. Furthermore, Sertoli cells under testosterone or DHT stimulation produce factors for the successful progression of spermatogenesis. Among them, there are secreted growth factors acting as paracrine factors to ensure the survival of germ cells as well as the progression of spermatogenesis, for exemple, IL-4, BMP-4, TGF␤, etc. (54) . So, we cannot exclude the possibility that other paracrine factors present in TCM are also participating in PFKFB isozyme regulation. This could explain, for example, the increased levels of Pfkfb3 mRNA when FGF-2 signaling is inhibited by the FGF receptor-specific inhibitor (SU-5402; Fig. 4D ). Hormonal upregulation of glucose uptake and lactate production though an autocrine action of FGF-2 on Sertoli cells has been demonstrated (17) . However, FGF-2 paracrine control of glycolysis in germ cells has not been studied extensively. TCM treatment increased the concentration of Fru-2,6-P 2 in the germ cells, promoting the glycolytic pathway. Therefore, PFKFB4 isozyme is sufficient to maintain and even increase the levels of Fru-2,6-P 2 that germ cells need to activate the glycolytic pathway. This isozyme shows kinase activity (90 mU/mg protein) and bisphosphatase activity (22 mU/mg protein) (50) . The resulting high kinase/bisphosphatase activity ratio contributes to the maintenance of the elevated rate of glycolysis for high-energy production in testis (5, (37) (38) (39) .
TCM effects involve the activation of ERK signaling, particularly ERK and MSK-1, which are phosphorylated after TCM or FGF-2 treatments (Fig. 5) . When the inhibitor of FGF receptor SU-5402 was added to the medium, the phosphorylation of ERK and MSK-1 was abolished. Furthermore, the action of TCM was reverted when specific MAPK inhibitors were used. Consequently, the ERK pathway is directly involved in TCM action, hence regulating germ cell metabolism. In the testis, the MAPK signaling pathway is involved in several processes, including the cell cycle progression and differentiation of germ cells, germ cell apoptosis, blood-testis barrier dynamics, and Sertoli and germ cell adhesion (review in Ref. 28 ). Initially, MSK was identified as a cAMP response element, hence activating CREB transcriptional activity and subsequent transcription of downstream target genes (61) . CREB contributes to testicular maturation through its involvement in cell proliferation and differentiation in developing testes. CREB phosphorylation gradually increases from spermatogonia to a maximum in spermatids as Pfkfb4 mRNA does (14, 19, 25) . Hence, we analyzed the relationship between the transcription factor CREB and the Pfkfb4 gene. Indeed, there are several genes containing CRE elements that have been shown to be activated specifically during the haploid phase of spermatogenesis, such as actin-capping protein (23) or transition protein-1 (55) . In the promoter of Pfkfb4, we have identified a CRE consensus element located at position Ϫ1,463 upstream the transcription start site. Although CREB is usually bound to the CRE promoter element, full transcriptional activity is associated with Ser 133 phosphorylation (61) . After germ cells are treated with TCM or BCM plus FGF-2, CREB is phosphorylated after TCM treatment. In addition, we confirm the involvement of CREB through pulldown assays. Thus, CREB integrates FGF-2 signaling via the ERK pathway by modifying PFKFB gene transcription in a cell type-dependent manner. Testosterone is needed for adult spermatogenesis; its action is critical for the completion of meiosis (entry into and progress through meiosis) and spermiogenesis. Studies of mouse models lacking androgen receptor in all tissues (ARKO mice) or in which androgen receptor is knocked out selectively in Sertoli cells (SCARKO mice) have confirmed that testosterone is required to maintain spermatogenesis (9, 13, 34, 56) . The lack of testosterone in rats chemocastrated with the GnRH antagonist Degarelix and, consequently, the predicted loss of expression of FGF-2 by Sertoli cells when gonadotropin stimulation is eliminated sustain the role of FGF-2 in the control of Pfkfb4 and Pfkfb3 gene expression.
In conclusion, this study reveals the molecular mechanism by which DHT modulates the expression of the gene Pfkfb4 and, therefore, the glycolysis in the germ cells. Based on the results presented here, we propose a model to explain the transcriptional control of PFKFB isozyme expression during spermatogenesis. Within the seminiferous tubules, testosterone acts in Sertoli cells to stimulate secretion of growth factors such as FGF-2 (64). As a result, FGF-2 interacts with its receptor in germ cells, activating the ERK signaling pathway and the binding of CREB to the Pfkfb4 promoter, inducing its transcription. According to this model, PFKFB isozyme expression during spermatogenesis is regulated through a complex network of paracrine signaling that is orchestrated by Sertoli cells.
